Jay S. Duker - Nov 1, 2021 Form 4/A - Amendment Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Operating Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Nov 1, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/9/2022, 04:09 PM
Date Of Original Report
Nov 3, 2021
Next filing
Feb 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Award $0 +240K $0.00 240K Nov 1, 2021 Common Stock 240K $11.47 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months.
F2 Due to an administrative error, the Reporting Person's previous Form 4 filed on November 3, 2021 incorrectly reported the Reporting Person receiving an option grant of 305,000 shares of common stock when it should have been reported as 239,700 shares of common stock.